Nicola Fazio

List of Publications by Year in Descending Order

215 papers	5,724 citations	39 h-index	69 g-index
232 ext. papers	6,912 ext. citations	5.1 avg, IF	5.35 L-index

#	Paper	IF	Citations
215	ENETS standardized (synoptic) reporting for neuroendocrine tumour pathology.. *Journal of Neuroendocrinology*, **2022**, e13100	3.8	1
214	Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis.. *Cancer Treatment Reviews*, **2022**, 104, 102338	14.4	1
213	Predicting resectability of primary tumor and mesenteric lymph-node masses in patients with small-intestine neuroendocrine tumors.. *Updates in Surgery*, **2022**, 1	2.9	
212	ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors.. *Journal of Neuroendocrinology*, **2022**, e13105	3.8	4
211	Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside.. *Current Oncology Reports*, **2022**, 1	6.3	0
210	Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. *Cancers*, **2022**, 14, 2501	6.6	2
209	Neuroendocrine Neoplasms (NENs). *UNIPA Springer Series*, **2021**, 1061-1089	0.1	
208	Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profile. *Expert Opinion on Drug Safety*, **2021**, 1-8	4.1	
207	Results of Surgical Resection of Locally Advanced Pulmonary Neuroendocrine Tumors. *Annals of Thoracic Surgery*, **2021**, 112, 405-414	2.7	4
206	Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. *Endocrine-Related Cancer*, **2021**,	5.7	14
205	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. *Cancer Treatment Reviews*, **2021**, 94, 102168	14.4	1
204	A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy. *Diagnostics*, **2021**, 11,	3.8	2
203	Outcomes of small-cell versus large-cell gastroenteropancreatic neuroendocrine carcinomas: A population-based study. *Journal of Neuroendocrinology*, **2021**, 33, e12971	3.8	1
202	Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials. *Cancer*, **2021**, 127, 2674-2682	6.4	2
201	Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2021**, 32, 439-451	10.3	30
200	Sex-Based Differences in Prognosis of Patients With Gastroenteropancreatic-Neuroendocrine Neoplasms: A Population-Based Study. *Pancreas*, **2021**, 50, 727-731	2.6	1
199	Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: Results from the international phase II TALENT trial (GETNE 1509).. *Journal of Clinical Oncology*, **2021**, 39, 4113-4113	2.2	1

198	Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. *Pharmaceuticals*, **2021**, 14,	5.2	3
197	First Results of Radioguided Surgery in Small Intestine Neuroendocrine Tumors with Y-DOTATOC. *Cancer Biotherapy and Radiopharmaceuticals*, **2021**, 36, 397-406	3.9	2
196	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). *Journal of Clinical Oncology*, **2021**, 39, 2304-2312	2.2	8
195	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study **2021**, 9,		9
194	Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis. *Journal of Endocrinological Investigation*, **2021**, 1	5.2	4
193	Multidisciplinary team approach for Merkel cell carcinoma: the European Institute of Oncology experience with focus on radiotherapy. *Tumori*, **2021**, 107, 145-149	1.7	2
192	Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. *Endocrine*, **2021**, 72, 268-278	4	4
191	New Approaches in Medical Therapies **2021**, 129-136		
190	Mixed Neuroendocrine and Non-neuroendocrine Neoplasms (Mi NEN) **2021**, 269-282		
189	Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?. *Current Treatment Options in Oncology*, **2021**, 22, 19	5.4	1
188	Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. *Journal of Translational Medicine*, **2021**, 19, 70	8.5	1
187	Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties. *Journal of Neuroendocrinology*, **2021**, 33, e13000	3.8	1
186	Alpelisib in combination with everolimus exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. *European Journal of Cancer*, **2021**, 151, 49-62	7.5	5
185	Reply to comments on 'COVID-19 in patients with neuroendocrine neoplasms: Preliminary results of a worldwide survey (The INTENSIVE study)'. *European Journal of Cancer*, **2021**, 157, 531-532	7.5	
184	Should temozolomide be used on the basis of O-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis. *Cancer Treatment Reviews*, **2021**, 99, 102261	14.4	2
183	Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study. *European Journal of Cancer*, **2021**, 154, 246-252	7.5	2
182	Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 17588359211029559	5.4	1
181	Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib. *Targeted Oncology*, **2021**, 16, 27-35	5	7

180	Personalizing Multimodal Treatment in Patients With Pancreatic Neuroendocrine Tumors. *JCO Oncology Practice*, **2020**, 16, 729-730	2.3	0
179	Cisplatin Plus Gemcitabine as Standard of Care for Germline -Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast?. *Journal of Clinical Oncology*, **2020**, 38, 2466-2467	2.2	5
178	HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).. *Journal of Clinical Oncology*, **2020**, 38, 638-638	2.2	28
177	Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study. *European Journal of Endocrinology*, **2020**, 182, 439-446	6.5	11
176	The rare entity of bilateral and unilateral neuroendocrine metastases to the breast: a case series and literature review. *Ecancermedicalscience*, **2020**, 14, 1123	2.7	4
175	Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. *Expert Opinion on Pharmacotherapy*, **2020**, 21, 2317-2324	4	
174	SARS-CoV-2-related pneumonia can be successfully managed in patients with metastatic neuroendocrine tumors: a critical point of view. *Endocrine*, **2020**, 70, 6-10	4	2
173	Ivosidenib for advanced IDH1-mutant cholangiocarcinoma. *Lancet Oncology, The*, **2020**, 21, e370	21.7	4
172	Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms. *Lung Cancer*, **2020**, 148, 149-158	5.9	9
171	Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. *Journal of Clinical Oncology*, **2020**, 38, 3185-3194	2.2	92
170	Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature. *Lung Cancer: Targets and Therapy*, **2020**, 11, 41-52	2.9	2
169	Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. *Future Oncology*, **2020**, 16, 2089-2099	3.6	1
168	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. *Annals of Surgery*, **2020**, 271, 527-533	7.8	27
167	Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin. *Neuroendocrinology*, **2020**, 110, 616-629	5.6	22
166	Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas. *Neuroendocrinology*, **2019**, 109, 100-112	5.6	14
165	Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. *Cancer Treatment Reviews*, **2019**, 80, 101895	14.4	22
164	Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. *Future Oncology*, **2019**, 15, 1997-2007	3.6	2
163	Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).. *Journal of Clinical Oncology*, **2019**, 37, 4106-4106	2.2	19

162	Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors (NETs): A pooled analysis of two phase II trials with pazopanib and lenvatinib.. *Journal of Clinical Oncology*, **2019**, 37, 4109-4109	2.2	2
161	Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): Updated results from the phase II TALENT trial (GETNE 1509).. *Journal of Clinical Oncology*, **2019**, 37, 332-332	2.2	4
160	Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. *Endocrine-Related Cancer*, **2019**, 26, 391-403	5.7	19
159	Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. *Endocrine-Related Cancer*, **2019**, 26, 227-239	5.7	67
158	Sunitinib in patients with pancreatic neuroendocrine tumors (panNETs): Exploratory pharmacogenomic analyses.. *Journal of Clinical Oncology*, **2019**, 37, 255-255	2.2	
157	Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors. *Expert Opinion on Drug Metabolism and Toxicology* , **2019**, 15, 993-1004	5.5	9
156	Unmet Needs in Appendiceal Neuroendocrine Neoplasms. *Neuroendocrinology*, **2019**, 108, 37-44	5.6	12
155	Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. *Neuroendocrinology*, **2019**, 108, 26-36	5.6	25
154	Neuroendocrine neoplasms of rectum: A management update. *Cancer Treatment Reviews*, **2018**, 66, 45-55	14.4	35
153	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. *Pancreatology*, **2018**, 18, 198-203	3.8	14
152	Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. *Surgery*, **2018**, 163, 761-767	3.6	47
151	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. *Gastroenterology*, **2018**, 155, 479-489.e7	13.3	36
150	Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. *Endocrine-Related Cancer*, **2018**, 25, 583-593	5.7	55
149	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. *Endocrine-Related Cancer*, **2018**, 25, 607-618	5.7	13
148	Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. *Neuroendocrinology*, **2018**, 106, 211-220	5.6	24
147	G3 GEP NENs category: are basic and clinical investigations well integrated?. *Endocrine*, **2018**, 60, 28-30	4	3
146	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. *Neuroendocrinology*, **2018**, 107, 237-245	5.6	32
145	: Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms. *Endocrine, Metabolic and Immune Disorders - Drug Targets*, **2018**, 18, 419-449	2.2	3

144	Therapy for Metastatic Disease with Unknown Primary Tumor **2018**, 335-342		
143	Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). *Annals of Oncology*, **2018**, 29, viii467-viii468	10.3	44
142	Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. *Cancer Science*, **2018**, 109, 174-181	6.9	42
141	Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2018**, 38, 292-299	7.1	6
140	A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors. *Journal of Thoracic Disease*, **2018**, 10, 3928-3939	2.6	11
139	Liver Resection or Resection plus Intraoperative Echo-Guided Ablation in the Treatment of Colorectal Metastases: We are Evaluating Their Effect for Cure. *American Surgeon*, **2018**, 84, 1509-1517	0.8	
138	Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509). *Annals of Oncology*, **2018**, 29, viii467	10.3	13
137	Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis. *Cancer Treatment Reviews*, **2018**, 71, 39-46	14.4	12
136	A rationale multidisciplinary approach for treatment of esophageal and gastroesophageal junction cancer: Accurate review of management and perspectives. *Critical Reviews in Oncology/Hematology*, **2018**, 132, 161-168	7	6
135	The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. *Neuroendocrinology*, **2017**, 104, 85-93	5.6	137
134	Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives. *Cancer Treatment Reviews*, **2017**, 55, 46-56	14.4	5
133	When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors?. *Journal of Clinical Oncology*, **2017**, 35, 1487-1488	2.2	1
132	Gastroenteropancreatic Neuroendocrine Carcinomas: The NET G3 Subcategory Is a Reality. *Oncologist*, **2017**, 22, 359	5.7	7
131	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. *European Journal of Endocrinology*, **2017**, 176, 453-461	6.5	39
130	Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors. *Cancer Treatment Reviews*, **2017**, 57, 28-35	14.4	11
129	Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors. *Targeted Oncology*, **2017**, 12, 611-622	5	14
128	Everolimus-related adverse events in neuroendocrine tumors and comparative considerations with breast and renal cancer: a critical overview. *Expert Opinion on Orphan Drugs*, **2017**, 5, 525-536	1.1	
127	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. *Cancer Medicine*, **2017**, 6, 1493-1499	4.8	9

126	Everolimus in Pancreatic Neuroendocrine Carcinomas G3. *Pancreas*, **2017**, 46, 302-305	2.6	37
125	High-risk human papillomavirus in anal squamous cell carcinoma: a 'conservative' leading role. *Annals of Oncology*, **2017**, 28, 1160	10.3	
124	A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. *Annals of Oncology*, **2017**, 28, 1309-1315	10.3	63
123	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy. *Neuroendocrinology*, **2017**, 105, 281-294	5.6	66
122	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. *Neuroendocrinology*, **2017**, 105, 212-244	5.6	196
121	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. *Neuroendocrinology*, **2017**, 105, 266-280	5.6	82
120	Regression of advanced neuroendocrine tumors among patients receiving placebo. *Endocrine-Related Cancer*, **2017**, 24, L13-L16	5.7	4
119	HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?. *Cancer and Metastasis Reviews*, **2017**, 36, 141-157	9.6	79
118	Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. *OncoTargets and Therapy*, **2017**, 10, 5013-5030	4.4	5
117	The role of multimodal treatment in patients with advanced lung neuroendocrine tumors. *Journal of Thoracic Disease*, **2017**, 9, S1501-S1510	2.6	14
116	Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncology, The*, **2017**, 18, 1411-1422	21.7	49
115	Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation. *European Journal of Surgical Oncology*, **2017**, 43, 372-379	3.6	38
114	Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. *Endocrine*, **2017**, 56, 633-638	4	25
113	Dual modulation of MCL-1 and mTOR determines the response to sunitinib. *Journal of Clinical Investigation*, **2017**, 127, 153-168	15.9	37
112	The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.. *Journal of Clinical Oncology*, **2017**, 35, 380-380	2.2	5
111	Grading lung neuroendocrine tumors: Controversies in search of a solution. *Histology and Histopathology*, **2017**, 32, 223-241	1.4	21
110	Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. *Endocrine*, **2016**, 51, 131-9	4	31
109	A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. *Endocrine Connections*, **2016**, 5, 174-87	3.5	63

108	Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. *Neuroendocrinology*, **2016**, 103, 531-7	5.6	18
107	Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. *Cancer Treatment Reviews*, **2016**, 50, 61-67	14.4	64
106	Optimizing treatment of hepatic metastases from colorectal cancer: Resection or resection plus ablation?. *International Journal of Oncology*, **2016**, 48, 1280-9	4.4	8
105	Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors. *Neuroendocrinology*, **2016**, 103, 806-14	5.6	38
104	Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. *Lancet, The*, **2016**, 387, 968-977	40	694
103	Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials. *Critical Reviews in Oncology/Hematology*, **2016**, 99, 1-12	7	16
102	Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. *Annals of Oncology*, **2016**, 27, 668-73	10.3	28
101	Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: Second interim overall survival (OS) results from the RADIANT-4 study.. *Journal of Clinical Oncology*, **2016**, 34, 4090-4090	2.2	5
100	A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. *Anticancer Research*, **2016**, 36, 713-9	2.3	57
99	Everolimus in combination with Octreotide LAR in first line setting for patients with neuroendocrine tumors (I.T.M.O. study): A 5-years update.. *Journal of Clinical Oncology*, **2016**, 34, 4092-4092	2.2	
98	Successful palliative approach with high-intensity focused ultrasound in a patient with metastatic anaplastic pancreatic carcinoma: a case report. *Ecancermedicalscience*, **2016**, 10, 635	2.7	8
97	Treatments for colorectal liver metastases: A new focus on a familiar concept. *Critical Reviews in Oncology/Hematology*, **2016**, 108, 154-163	7	25
96	Long-term results of PRRT in advanced bronchopulmonary carcinoid. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 441-52	8.8	78
95	Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases. *Annals of Surgical Oncology*, **2016**, 23, 981-989	3.1	42
94	Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside. *Cancer Treatment Reviews*, **2015**, 41, 754-60	14.4	19
93	Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making. *International Journal of Surgery*, **2015**, 20, 58-64	7.5	15
92	Nonfunctioning Pancreatic Neuroendocrine Tumors **2015**, 275-298		
91	Human papillomavirus in anal squamous cell carcinoma: an angel rather than a devil?. *Ecancermedicalscience*, **2015**, 9, 529	2.7	8

90	Medical Therapy of Pancreatic Neuroendocrine Neoplasms **2015**, 191-195		
89	Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects. *Neuroendocrinology*, **2015**, 101, 274-88	5.6	48
88	Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET).. *Journal of Clinical Oncology*, **2015**, 33, 4102-4102	2.2	9
87	Neuroendocrine tumors resistant to mammalian target of rapamycin inhibitors: A difficult conversion from biology to the clinic. *World Journal of Clinical Oncology*, **2015**, 6, 194-7	2.5	11
86	Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumors. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2015**, 59, 446-54	1.4	8
85	Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. *Cancer*, **2014**, 120, 2457-63	6.4	52
84	RAF signaling in neuroendocrine neoplasms: from bench to bedside. *Cancer Treatment Reviews*, **2014**, 40, 974-9	14.4	16
83	Cost effectiveness of different central venous approaches for port placement and use in adult oncology patients: evidence from a randomized three-arm trial. *Annals of Surgical Oncology*, **2014**, 21, 3725-31	3.1	24
82	Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. *Human Pathology*, **2014**, 45, 665-73	3.7	19
81	Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach. *Surgery*, **2014**, 155, 607-14	3.6	55
80	Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey. *PLoS ONE*, **2014**, 9, e105268	3.7	25
79	Prognostic value of human papillomavirus in anal squamous cell carcinoma. *Cancer Chemotherapy and Pharmacology*, **2014**, 74, 1033-8	3.5	20
78	Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. *Journal of Endocrinological Investigation*, **2014**, 37, 875-909	5.2	16
77	Real-world study of everolimus in advanced progressive neuroendocrine tumors. *Oncologist*, **2014**, 19, 966-74	5.7	66
76	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. *Annals of Oncology*, **2014**, 25, 1373-1378	10.3	61
75	Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. *BMC Cancer*, **2014**, 14, 184	4.8	61
74	Capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NEN): An Italian multicenter retrospective analysis.. *Journal of Clinical Oncology*, **2014**, 32, 281-281	2.2	7
73	Molecular targeted therapy in enteropancreatic neuroendocrine tumors: from biology to clinical practice. *Current Medicinal Chemistry*, **2014**, 21, 1017-25	4.3	8

72	Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. *Ecancermedicalscience*, **2014**, 8, 463	2.7	25
71	Updated overall survival and time to progression results in NETs treated with everolimus combination with octreotide LAR as first-line treatment.. *Journal of Clinical Oncology*, **2014**, 32, e15160-e15160	2.2	
70	ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. *Cancer Chemotherapy and Pharmacology*, **2013**, 72, 159-65	3.5	37
69	Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view. *Cancer Treatment Reviews*, **2013**, 39, 270-4	14.4	51
68	Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. *Chest*, **2013**, 143, 955-962	5.3	95
67	Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group.. *Journal of Clinical Oncology*, **2013**, 31, 4136-4136	2.2	2
66	Long-term survival after multidisciplinary treatment of small-bowel neuroendocrine tumors with synchronous liver metastases.A single-institute experience.. *Journal of Clinical Oncology*, **2013**, 31, 299-299	2.2	
65	Long-term survival after multidisciplinary treatment of small-bowel neuroendocrine tumors with synchronous liver metastases: A single-institute experience.. *Journal of Clinical Oncology*, **2013**, 31, e15147-e15147	2.2	
64	La terapia medica dei tumori neuroendocrini. *L Endocrinologo*, **2012**, 13, 158-162	0	
63	Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. *Neuroendocrinology*, **2012**, 96, 32-40	5.6	44
62	Clinical Response after Sorafenib for Hepatocellular Carcinoma in Elderly Patients: A Report of Two Cases. *Tumori*, **2012**, 98, e53-e56	1.7	2
61	Pregnant with metastatic neuroendocrine tumour of the ovary: what now?. *Ecancermedicalscience*, **2012**, 6, 240	2.7	3
60	Hepatic intra-arterial chemotherapy in patients with advanced primary liver tumours. *Ecancermedicalscience*, **2012**, 6, 280	2.7	2
59	Merkel cell polyomavirus in gastrointestinal neuroendocrine tumors.. *Journal of Clinical Oncology*, **2012**, 30, 4120-4120	2.2	
58	Clinical response after sorafenib for hepatocellular carcinoma in elderly patients: a report of two cases. *Tumori*, **2012**, 98, 53e-56e	1.7	
57	Successful Treatment with GEMOX in Patient with Metastatic Pancreatic Adenosquamous Carcinoma. *Tumori*, **2011**, 97, 239-242	1.7	4
56	Perfusion computed tomography in patients with hepatocellular carcinoma treated with thalidomide: initial experience. *Journal of Computer Assisted Tomography*, **2011**, 35, 195-201	2.2	20
55	No impact of central venous insertion site on oncology patients' quality of life and psychological distress. A randomized three-arm trial. *Supportive Care in Cancer*, **2011**, 19, 1573-80	3.9	13

54	Peptide receptor radionuclide therapy with □□u-DOTATATE: the IEO phase I-II study. *European Journal of Nuclear Medicine and Molecular Imaging*, **2011**, 38, 2125-35	8.8	287
53	High intensity focused ultrasound ablation of pancreatic neuroendocrine tumours: report of two cases. *CardioVascular and Interventional Radiology*, **2011**, 34, 419-23	2.7	20
52	Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. *Journal of Clinical Oncology*, **2011**, 29, 2372-7	2.2	216
51	Neuroendocrine tumour arising inside a retro-rectal tailgut cyst: report of two cases and a review of the literature. *Ecancermedicalscience*, **2011**, 5, 201	2.7	17
50	ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. *Neuroendocrinology*, **2010**, 91, 333-40	5.6	41
49	Adjuvant colon cancer chemotherapy: where we are and where we'll go. *Cancer Treatment Reviews*, **2010**, 36 Suppl 3, S34-41	14.4	58
48	Molecularly targeted endocrine therapies for breast cancer. *Cancer Treatment Reviews*, **2010**, 36 Suppl 3, S67-71	14.4	49
47	Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. *Cancer Treatment Reviews*, **2010**, 36 Suppl 3, S87-94	14.4	31
46	Carboplatin with etoposide in patients with extrapulmonary □ggressive□neuroendocrine carcinoma.. *Journal of Clinical Oncology*, **2010**, 28, e13072-e13072	2.2	3
45	Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. *World Journal of Gastroenterology*, **2010**, 16, 868-74	5.6	56
44	A possible connective tissue primary lymphoepithelioma-like carcinoma (LELC). *Ecancermedicalscience*, **2010**, 4, 197	2.7	3
43	Right pelvic mass in a patient with a radically resected carcinoid of the appendix. *Gut*, **2009**, 58, 1200, 1259	19.2	
42	Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. *Annals of Oncology*, **2009**, 20, 935-40	10.3	157
41	The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy. *Critical Reviews in Oncology/Hematology*, **2009**, 72, 65-75	7	27
40	Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. *Cancer Chemotherapy and Pharmacology*, **2009**, 64, 301-6	3.5	9
39	Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives. *Critical Reviews in Oncology/Hematology*, **2009**, 72, 110-24	7	32
38	Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. *International Journal of Radiation Oncology Biology Physics*, **2009**, 75, 421-7	4	30
37	Vinorelbine, cisplatin, and continuous infusion of 5-fluorouracil (ViFuP regimen) in carcinoma of unknown primary. *Journal of Clinical Oncology*, **2009**, 27, e20682-e20682	2.2	

36	Miliary hepatic metastases from neuroendocrine carcinoma. *Digestive Surgery*, **2008**, 25, 330	2.5	6
35	Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy. *Anti-Cancer Drugs*, **2008**, 19, 837-40	2.4	5
34	Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?. *Cancer Chemotherapy and Pharmacology*, **2008**, 63, 139-48	3.5	10
33	Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients. *World Journal of Surgical Oncology*, **2007**, 5, 73	3.4	63
32	Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. *Digestive and Liver Disease*, **2007**, 39, 537-43	3.3	30
31	Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?. *Annals of Oncology*, **2007**, 18, 13-19	10.3	70
30	Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. *Journal of the National Cancer Institute*, **2007**, 99, 1345-6; author reply 1346-7	9.7	4
29	Successful treatment with low-dose oral chemotherapy in a patient with metastatic hepatocellular carcinoma. *Acta Oncologica*, **2007**, 46, 1205-6	3.2	2
28	Temsirolimus for advanced renal-cell carcinoma. *New England Journal of Medicine*, **2007**, 357, 1050; author reply 1050-1	59.2	4
27	Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. *Journal of Clinical Oncology*, **2007**, 25, 3217-23	2.2	219
26	Thalidomide in patients with advanced hepatocellular carcinoma: A clinical/biological study. *Journal of Clinical Oncology*, **2007**, 25, 15076-15076	2.2	2
25	Resection of colorectal liver metastases following neoadjuvant chemotherapy. *Ecancermedicalscience*, **2007**, 1, 58	2.7	
24	Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. *Annals of Oncology*, **2006**, 17, 1174-5	10.3	12
23	Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma. *Acta Oncologica*, **2006**, 45, 627-9	3.2	6
22	Hepatic intra-arterial chemotherapy in patients with metastatic breast cancer. *Journal of Clinical Oncology*, **2006**, 24, 10581-10581	2.2	
21	Langerhans' cell histiocytosis. *Lancet, The*, **2005**, 365, 598	40	1
20	Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003. *International Journal of Colorectal Disease*, **2005**, 20, 221-30	3	17
19	Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain. *Supportive Care in Cancer*, **2005**, 13, 194-5	3.9	6

18	Target-treatment and patients' selection: can we still neglect the timing of tissue collection?. *Journal of Clinical Oncology*, **2005**, 23, 6274-5; author reply 6275-6	2.2	2
17	First-line gefitinib combined with simplified FOLFOX-6 in patients with epidermal growth factor receptor-positive advanced colorectal cancer. *Journal of Clinical Oncology*, **2005**, 23, 3659-3659	2.2	9
16	Should interferon- and somatostatin analogs be combined in gastroenteropancreatic neuroendocrine tumor therapy?. *Therapy: Open Access in Clinical Medicine*, **2005**, 2, 229-235		
15	Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors. *Journal of Clinical Oncology*, **2004**, 22, 573-4; author reply 574-5	2.2	4
14	CDX-2 should be included in the work-up of patients with lung metastases from unknown primary. *Annals of Oncology*, **2004**, 15, 1850	10.3	1
13	5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. *Annals of Oncology*, **2004**, 15, 759-64	10.3	38
12	Irinotecan combined with infusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemotherapy. *Journal of Clinical Oncology*, **2004**, 22, 4146-4146	2.2	
11	Irinotecan combined with infusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemotherapy. *Journal of Clinical Oncology*, **2004**, 22, 4146-4146	2.2	
10	Docetaxel in advanced gastric cancer--review of the main clinical trials. *Acta Oncologica*, **2003**, 42, 693-700	3.2	21
9	Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma. *Annals of Oncology*, **2003**, 14, 803-4	10.3	12
8	Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma. *Anticancer Research*, **2003**, 23, 5023-30	2.3	5
7	Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). *Annals of Oncology*, **2000**, 11, 301-6	10.3	156
6	CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2000**, 437, 270-4	5.1	39
5	5FU as protracted continuous IV infusion (5FUpiv) can be added to full dose taxotere-cisplatin (TC) in advanced gastric carcinoma (AGC). *European Journal of Cancer*, **1999**, 35, S139	7.5	6
4	Practical considerations in the treatment of hepatocellular carcinoma. *Drugs*, **1998**, 55, 367-82	12.1	18
3	High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?. *Annals of Oncology*, **1998**, 9, 917-9	10.3	31
2	Activity and Tolerability of Courses of Intra-Arterial Chemotherapy Followed by Chemoembolization in Unresectable Hepatocellular Carcinoma. *Tumori*, **1998**, 84, 673-676	1.7	2
1	No effect of cloricromen on some coagulation parameters in patients with ischaemic cerebrovascular disease. *Journal of International Medical Research*, **1994**, 22, 287-91	1.4	1